Background. IgA nephropathy (IgAN) is not generally considered a hereditary disease, even though extensive evidence suggests an undefined genetic influence. Linkage analysis identified a number of genome regions that could contain variations linked to IgAN. Methods. In this case-control association study, genes possibly involved in the development of IgAN were investigated. DNA samples from 460 North Italian patients with IgAN and 444 controls were collected. Candidate genes were selected based on their possible functional involvement (6 genes) or because of their location within linkage-identified genomic regions IGAN2 and IGAN3 (5 and 13 genes within chromosome 4q26-31 and 17q12-22, respectively). One hundred and ninetytwo tag and functional single-nucleotide polymorphisms (SNPs) were typed with Veracode GoldenGate technology (Illumina). Results. C1GALT1 showed an association with IgAN (rs1008898: P ¼ 0.0019 and rs7790522: P ¼ 0.0049). Associations were found when the population was stratified by gender (C1GALT1, CD300LG, GRN, ITGA2B, ITGB3 in males and C1GALT1, TRPC3, B4GALNT2 in females) and by age (TLR4, ITGB3 in patients aged <27 years). Furthermore, rs7873784 in TLR4 showed an association with proteinuria (G allele: P ¼ 0.0091; GG genotype: P ¼ 0.0077). Conclusions. Age and gender are likely to evidence distinct immunological and inflammatory reactions leading to individual susceptibility to IgAN. Overall, a genetic predisposition to sporadic IgAN was found. We might hypothesize that C1GALT1 and TLR4 polymorphisms influence the risk to develop IgAN and proteinuria, respectively.
Introduction
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Nonetheless, mechanisms regulating abnormal IgA synthesis and its selective mesangial deposition, mesangial cell proliferation and extracellular matrix expansion leading to renal fibrosis are still poorly understood [1] [2] [3] [4] .
Although not generally considered a hereditary disease, IgAN ethnic variation in prevalence and familial clustering have suggested an undefined genetic influence [5] [6] [7] [8] [9] . IgAN does not exhibit basic Mendelian segregation patterns, although an increased risk of the disease was observed in close relatives of probands. The heterogeneity of the IgAN phenotype is more consistent with the combined effects of variation at multiple interacting genes and the environment [6, 8] . The first report on genome-wide linkage analysis in familial IgAN identified a genetic locus on chromosome 6q22-23 (IGAN1) [10] . Linkage analysis to IGAN1, in an independent group of Italian IgAN families, evidenced that the majority are not linked to this locus confirming genetic heterogeneity in familial IgAN. Bisceglia et al. [11] and Paterson et al. [12] found the existence of other candidate chromosomal regions on 4q, 7q, 12q, 17q and 2q. The regions 4q26-31 and 17q12-22 exhibited the strongest evidence of linkage from two point, multipoint parametric and non-parametric linkage analysis becoming the second (IGAN2) and third (IGAN3) genetic loci candidate to contain causative and/or susceptibility genes to familial IgAN [11] .
Case-control studies have been long heralded as the optimal design to discover gene variation associated with genetic susceptibility to complex multifactorial diseases [13] , and they have been successfully applied to a host of complex diseases [14] . IgAN may also follow this multifactorial paradigm, and hence, a case-control design may be successful in recovering genetic susceptibility factors.
In this study, the genotype of 23 candidate genes selected on the base of their functional possible involvement (6 genes) or because mapping in the genomic regions IGAN2 (5 genes) and IGAN3 (13 genes) were retrospectively evaluated in 460 Italian patients affected by IgAN, to search for single nucleotide polymorphisms (SNPs) correlated with the development and the clinical course of this disease.
Materials and methods

Patients
Four hundred and sixty DNA samples (446 successfully genotyped) of North Italian patients affected by IgAN were collected; 188 (185) of them were from Brescia, 45 (42) from Cremona, 35 (34) from Bologna, 21 (21) from Trieste and 171 (164) from Turin. The pathology was diagnosed by performing renal biopsy (RB) between the years 1966 and 2003 and patients with Henoch-Schonlein purpura were excluded. Patient characteristics, including gender, age at time of RB, serum creatinine (sCr), proteinuria (PTU) and creatinine clearance (CrCl) at time of RB, dialysis, transplantation, relapse after transplantation and Lee's classification, are shown in Table 1 . This study was approved by local ethical committees of involved hospitals and informed consent was obtained from each subject. Two hundred and twenty-eight IgAN patients of Brescia, Cremona, Bologna and Trieste have already been included in the previous association study of Pirulli et al. [15] , where eight polymorphisms of C1GALT1 were analysed. In the present study, we selected 10 different SNPs of C1GALT1, with the exception of rs1008898, located in the 5#flanking region at position À330, that was in common with the previous study. The other seven SNPs of the previous study were not considered in this work because they did not pass our criterion of selection.
In order to perform a case-control association study and to reflect a similar geographic origin of patients, a healthy North Italian population (n ¼ 444; 429 successfully genotyped) was also typed as control: they belong to negative urinalysis unrelated individuals, mainly blood or bone marrow donors. We collected 86 (84 successfully genotyped) controls from Brescia, 43 (40) from Cremona, 24 (24) from Bologna, 16 (15) from Trieste and 275 (266) from Turin (Table 1) . To reflect a similar geographic origin (the only difference is the lower number of controls from Brescia, that we supplied with a higher number of controls from Turin) and because of the selection within blood and marrow donors, controls could not match patients for age and sex.
Gene selection
Two main strategies were used in order to select 23 genes. The first is candidate gene approach based on their functional possible involvement in IgAN. Six genes, already analysed in previous studies, were evaluated: the core-1-b,3-galactosyltransferase (C1GALT1) [15, 16] and its specific molecular chaperone b1,3-GT (C1GALT1C1) [17, 18] , GalNAc a2,6-sialyltransferase (ST6GALNAC2) [19, 20] , transferrin receptor 1 (TFRC) [21, 22] , immunoglobulin A Fca receptor (CD89) [23, 24] and toll-like receptor 4 (TLR4) [25, 26] (Table 2) .
By the second approach, public databases were queried to obtain the available gene maps for 4q24-31 (IGAN2; 21cM) and 17q12-22 (IGAN3; 15cM) chromosomal linked regions [11] and the information on the expression pattern of these genes in tissue and organs (www.hapmap.org, www.ensembl.org). Genes of potential interest located on IGAN2 were selected: the transient receptor potential channel 3 (TRPC3) [45] and interleukin 21 (IL21) [46, 47] , complement factor I (CFI) [1, 42] , aminopeptidase A ectopeptidase (ENPEP) [43, 44] and nephronectin (NPNT) [41] (Figure 1 ). On IGAN3 different chemokines (CCL2, CCL3, CCL5, CCL7) were selected and a chemokine receptor (CCR7) [27, 28] , granulin (GRN) [31, 32] , a and b subunits of the platelet adhesive glycoprotein receptor complex GPIIb/IIIa (ITGA2B and ITGB3) and integrin a3 (ITGA3) [33] [34] [35] [36] [37] . Furthermore, the hepatocyte nuclear factor-1-b (HNF1B) [29] , CD300 antigen-like family member G (CD300LG) [30] , TBX21 [38, 39] and b-1,4-N-acetyl-galactosaminyltransferase2 (B4GALNT2) [40] were analysed [ Figure 2 , (see Supplementary data for colour version) Table 2 ]. The last set of genes have never been analysed in previous studies for association to IgAN (Supplementary data).
SNP selection and genotyping
Peripheral blood from patients and controls was collected in ethylene diamine tetra-acetic acid, and genomic DNA was extracted by 'salting out' method [48] or automatically (Macherey-Nagel kit). Electrophoresis was carried out using 2% agarose, stained with ethidium bromide and visualized by ultraviolet transillumination. All DNA samples were quantified with the PicoGreen method.
Within Table 2) .
The 192 selected SNPs (179 successfully genotyped) were analysed with the Veracode GoldenGate technology (Illumina), a multiplex recent testing method based on digitally encoded microbeads. A designability rank score (0-1.0) was calculated for each SNP by Illumina for the conversion of a SNP into a successful GoldenGate assay. Of the 192 SNPs, 170 with a score >0.6 (designability rank ¼ 1, high success rate) and 20 with a score between 0.4 and 0.6 (designability score ¼ 0.5, moderate success rate) were selected (Supplementary data: Illumina SNPs list). The Illumina GoldenGate assay was performed according to the manufacturer's protocol.
For the total number of samples, the call frequency [the frequency of the total number of genotypes in each sample with a GenCall (GC) score above the no-call threshold, from 0 to 1] was 1 for 78 SNPs, between 0.893 and 0.999 for 121 SNPs and 0 for 13 SNPs (not successfully genotyped). Seven loci of the 13 failed SNPs were not successfully genotyped because of the cluster separation, 2 because of the low intensity, 2 because >3 clusters were detected, 1 because an allele failed and 1 because detected only a single cluster was detected (Supplementary data: Illumina Results, Illumina GenomiPhi Results).
The automatic allele calling was done using the Illumina GenCall software with a GC threshold of 0.25. The software assigned three clusters on a graph based on the fluorescence obtained (Supplementary data: Illumina Results, Illumina GenomiPhi Results). The GC score, a confidence score of the genotyping of each point, depends on the intensity of fluorescence and the distance of the point from the centre of the cluster on the graph. The obtained values for each SNPs across all samples referred to as the 50 or 10% GC score is listed in Supplementary data: Illumina Results, Illumina GenomiPhi Results and detailed in Tables 3, 5 and 6 for the SNPs with a significant P-value.
Statistical analysis
Allele and genotype frequencies were calculated by direct gene counting. Hardy-Weinberg (H-W) equilibrium was calculated on the basis of expected genotype frequencies. Both simple analyses, such as the study of allele or genotyping frequencies and the H-W equilibrium, and higher scale analyses such as LD, haplotype estimations and allele and genotype association analyses were performed using the SNPator bioinformatic tool [49] and SPSS (SPSS Inc., Chicago, IL). We considered P < 0.01 as the significance cut-off and value. We applied the Bonferroni correction for multiple testing for all comparisons [P c -value was adjusted for 179 SNPs (179 of 192 SNPs were successfully genotyped) and P c -values <0.05 were considered as significant], with the exception of C1GALT1, as it was already associated with IgAN in previous studies. Odds ratios (ORs) were adjusted for sex and age with logistic regression as implemented in SNPstats (http://bioinfo.iconcologia.net/snpstats/start.htm). Power analysis was also performed and applied to each statistical significant association. Our sample size is adequate to achieve 80% power at P < 0.05 to detect a positive association for each polymorphism, but not sufficient at P < 0.01.
Results
Four hundred and sixty DNA samples (446 successfully genotyped) of North Italian patients affected by IgAN were collected. A healthy North Italian population (n ¼ 444; 429 successfully genotyped) geographically matched with patients was also typed as control. Patient characteristics are listed in Table 1 .
One hundred and ninety-two SNPs were genotyped (179 successfully). Polymorphisms were carefully selected within candidate genes by function (C1GALT1, C1GALT1C1, TFRC, FCAR, TLR4, ST6GALNAC2) and by mapping in two genomic regions, IGAN2 (NPNT, CFI, ENPEP, TRPC3, IL21; Figure 1 , see Supplementary data for colour version) and IGAN3 (CCL2, CCL7, CCL5, CCL3, HNF1B, CCR7, CD300LG, GRN, ITGA2B, ITGB3, TBX21, B4GALNT2, ITGA3; Figure 2 ) ( Table 2) . Quality control details can be found in Supplementary data. No statistically significant departures from H-W equilibrium were found. (Figure 3 , see Supplementary data for colour version). These SNPs resulted in almost complete LD (D# ¼ 0.95, Haploview, www.hapmap.org). To verify these associations, the analysis was performed with patients (n ¼ 232) not included in the study of Pirulli et al. [15] and the association was marginally replicated (rs1008898: GG 1 GT versus TT genotype; P ¼ 0.0468; OR ¼ 2.48; 95% CI ¼ 0.99-6.22).
Overall, no significant associations in genotype frequencies were observed for the genes in the IGAN2 and IGAN3 genome regions (Figure 4 , Figure 5 , see Supplementary data for colour versions).
Gender
The patient population was stratified by gender (males: n ¼ 361, 78%; females: n ¼ 99, 22%). In males, various SNPs of different genes showed an association with the risk to develop IgAN: rs1008898, rs13245879 and rs7790522 of C1GALT1; rs12453522 of CD300LG, rs4792938 of GRN, two SNPs of ITGB3 (rs5918 and rs4629024) and one of ITGA2B (rs850730) ( Table 3) .
Also in females, different SNPs were found to be associated with IgAN: rs10263069 of C1GALT1, rs3796892 of ENPEP, rs6820068 of TRPC3 and two SNPs of B4GALNT2, rs4550490 and rs1403528; the last one remains statistical significant after Bonferroni correction (Table 3) .
Different haplotypes resulted from each gene with at least one SNP associated with IgAN which were analysed in males and females. Each haplotype was compared both with the most common haplotype and with all the other haplotypes. In males, the GAAGA and GGAGC haplotypes of CD300LG were associated, respectively, with a higher and a lower risk to develop IgAN and GT and CT haplotypes of ITGA2B with a higher and a lower risk, respectively (Table 4) . Furthermore, GCGATTGCCTGGGAT haplotype of ITGB3, when analysed versus all the other haplotypes, is associated with a higher risk to develop IgAN (Table 4 ). In females, the most common haplotype of B4GALNT2 (GAATGACGA), in both the analyses with six different haplotypes and with all the other haplotypes, is associated with a lower risk to develop IgAN (Table 4) .
Age at time of RB
IgAN shows a great diversity in age at onset, which may signal heterogeneity in its genetic architecture. Therefore, patient populations were stratified by quartiles into different groups of age at RB. Frequencies between minor and major quartiles were compared: the first included patients aged <27 years (n ¼ 126, 31%) and the second patients aged >48 years (n ¼ 84, 21%). In patients aged <27 years, an association between the risk to develop IgAN and rs4449421 of NPNT was found as well as rs7873784 of TLR4 and four SNPs of ITGB3, rs2015049, rs2292867, rs5918 and rs3809865 (Table 5) .
In patients aged >48 years, rs3917878 of CCL2, rs7224013 of CCL7 and rs2290065 of CCR7 resulted in association with the disease (Table 5) .
Since ITGB3 showed an association with the risk to develop IgAN both for males and young patients, an analysis in males aged <27 years was performed and an association of rs5918 SNP was found (Table 5) . Significant genotypic associations within sex and age classes were confirmed by means of logistic regression with both sex and age class as covariates, by means of the SNPstats programme (Table 3, Table 5 ) (http://bioinfo. iconcologia.net/SNPstats) [50] .
Clinical characteristics
Patients were also stratified according to several clinical parameters, which could represent endophenotypes. Hypertension, serum creatinine level, creatinine clearance, proteinuria at RB and outcome such as dialysis, renal transplantation and relapse of IgAN after transplantation were analysed. An association between IgAN with mild proteinuria (<3 g per day) and three SNPs of C1GALT1 (rs1008898, rs13245879 and rs7790522) was found as well as between IgAN with severe proteinuria (>3 g per day) and one SNP of TLR4 (rs7873784) ( Table 6 ).
Discussion
In this study, a comprehensive scan for genotype association in Italian IgAN patients was provided for the first time. One hundred and ninety-two selected polymorphisms were analysed in 23 genes in a large homogeneous North Italian population using high-throughput SNP genotyping. Genes were carefully selected based on their possible functional involvement in IgAN (6 genes) or because of their location within two candidate regions in linkage with the disease, the first on chromosome 17q12-22 (IGAN3, 13 genes) and the second on chromosome 4q26-31 (IGAN2, 5 genes) [11] .
The heterogeneity of the IgAN phenotype seems to be consistent with the combined effects of multiple interacting polymorphic genes and environmental factors [7, 11, 51, 52] . One of the difficulties in predicting the genetic influence of the susceptibility to IgAN is the involvement of immunologic factors and extracellular matrix rearrangements, which could affect the pathogenesis of IgAN. Age and gender are likely to evidence distinct immunological and inflammatory reactions leading to individual susceptibility to IgAN. Our results suggest a genetic involvement in IgAN, especially when stratified for gender, age and proteinuria.
Firstly, candidate genes selected by function were analysed. In the cohort of North Italian patients affected by IgAN, two polymorphisms (rs1008898 and rs7790522) of C1GALT1, the core-1-b1,3-galactosyltransferase, already known to be involved in glycosylation of IgA1 [15, 16] , showed an association with the risk to develop IgAN. Furthermore, rs1008898 is described to be in LD with rs11772919 (D# ¼ 0.69), an SNP correlated with the expression of C1GALT1 (http://eqtl.uchicago.edu). This is further evidence that the C1GALT1 gene is associated with the disease and suggests that its modified expression, possibly due to different SNPs, might be involved in the hypoglycosylation of IgA1. C1GALT1 also showed an association, with different SNPs, in males and females separately and in patients with mild proteinuria (<3 g per day) .
When the population was stratified by age, SNP rs7873784 in the TLR4 gene showed an association in individuals aged <27 years and in patients with severe proteinuria (>3 g per day). TLR4 expression has been recently investigated in IgAN by Coppo et al. [26] and its engagement in circulating mononuclear cells has suggested a role in the development of glomerular inflammation and a possible specific involvement in IgAN. Yoon et al. [53] proposed that serum CD14, a TLR4 ligand on the surface of macrophages/monocytes, affect IgAN progression, modulating the mesangial responsiveness to deposited IgA [54] . It might be hypothesized that rs7873784 in TLR4 (or other SNPs in LD with it) might up-regulate the production of TLR4, although we could not find any data correlating TLR4 expression with its SNPs (http://eqtl.uchicago.edu).
Secondly, the selected linked regions were analysed. On IGAN3, an association between the risk to develop IgAN in males and rs12453522 of CD300LG was found. The amino acid sequence of the immunoglobulin (Ig) V-like domain of CD300LG glycoprotein shows~35% identity to those of the polymeric Ig receptor (pIgR) and of Fca/muR [30] , generating a possible binding for IgA. SNP rs4792938 in granulin gene (GRN), which may be involved in immune response dysregulation [31, 32] , also showed an association. Granulin is a pluripotent secreted growth factor that mediates cell cycle progression and cell motility [32] . This SNP might change the expression of the gene, thereby contributing to the susceptibility to IgAN. Furthermore, SNPs of ITGA2B (rs850730) and ITGB3 (rs4629024 and rs5918) integrins, the a and b subunits of the platelet adhesive glycoprotein receptor complex GPIIb/IIIa, might also be involved. ITGB3 was also found in association with IgAN in individuals aged <27 years, particularly in males. Among other functions, integrins mediate platelet aggregation through binding of plasma fibrinogen and serve as receptor for platelet adhesion to the extracellular cell matrix in vivo [36] . They also regulate mesangial cell proliferation and deposition of excessive extracellular matrix [33] [34] [35] [36] [37] , which is a recognized risk factor for progression of IgAN. The detected SNPs of IT-GA2B and ITGB3 might enhance the expression of these genes and lead to the rearrangement of cellular matrix, triggering mesangial depositions and susceptibility to IgAN. Literature reports that, when stratified for gender, GRN is associated with Alzheimer disease [55] and ITGB3 with the metabolic syndrome in female patients [56] .
In females, B4GALNT2 showed an association with IgAN. B4GALNT2 catalyses the addition of an N-acetylgalactosamine residue via a b-1,4 linkage to a subterminal galactose residue substituted with an a-2,3-linked sialic acid [40] . Among other functions, B4GALNT2 was supposed to change the expression of von Willebrand factor (vWF) and may be relevant in type I von Willebrand disease, characterized by reduced levels of plasma vWF [57] [58] [59] . B4GALNT2 might influence the rearrangement of cellular matrix in IgAN and susceptibility to the disease, but further investigations on gene expression and molecular mechanisms even in IgA glycosylation are needed. Finally, the IGAN2 region was analysed. Genes in association with the risk to develop IgAN were found in females: ENPEP, that may affect the renin-angiotensin system [43, 44] , TRPC3, the transient receptor potential channel 3 [45] , and NPNT, in individuals aged <27 years, that may play a role in maintaining kidney filtration barrier [41] .
Taken together, these findings suggest a genetic predisposition to sporadic IgAN. In this study, several genes were analysed in IgAN for the first time, tag and functional SNPs being selected with MAF >0.05 and >0.01, respectively. For this reason, rare SNPs cannot be excluded to be associated with the disease as well as polymorphisms in other genes within IGAN2 and IGAN3 that we did not analyse. Other variants, such as insertion/deletion and copy number variations, were excluded for technical reasons and some SNPs did not pass the Illumina bioinformatics prediction of typing. Our sample size is adequate to achieve 80% power at P < 0.05 to detect a positive association for each polymorphism, but not sufficient at P < 0.01. Population stratification for sex and age may be a potential source of spurious associations, but this study does not argue to be a genome-wide association study; we analysed a few SNPs in a small number of selected candidate genes only in North Italian population samples and it does not claim overall significance for any SNP. Finally, although the North Italian population can be considered genetically homogeneous [60] , any genetic stratification would also confound the present study, with a potential to create false positives. Therefore, we could consider our results as preliminary for future studies.
Moreover, clinical data of the analysed population were partially lacking and different clinical characteristic collected at time of RB could be influenced by environmental factors and medical treatments. Excluding proteinuria, this could be a reason for the inefficiency of the analysis with clinical characteristics.
Overall, we might confirm the influence of C1GALT1 on the susceptibility to IgAN and hypothesize a role of TLR4 on proteinuria. A significant association between B4GALNT2 and the disease was also found, and it might be an interesting starting point for future analyses. Expression studies and other investigations in different populations with a larger sample size should be performed in order to replicate these results and to identify a possible causative gene variant for the disease. Genome-wide association studies, given their recent success in a number of common diseases, could also contribute to detect additional susceptibility genes for IgAN. Genetic factors possibly involved in the disease may be used for many purposes such as prognosis and to develop an IgAN 'risk index', which may improve new strategies to reduce disease risk factors and eventually lead to a better treatment of the disease.
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